Video

Dr. Bhat on ELEVATE-TN Results in Treatment-Naïve CLL

Seema A. Bhat, MD, discusses the results of the phase 3 ELEVATE-TN trial in patients with treatment-naïve CLL.

Seema A. Bhat, MD, a hematologist specializing in chronic lymphocytic leukemia (CLL) at The Ohio State University Comprehensive Cancer Center–James, discusses the results of the phase 3 ELEVATE-TN trial in patients with treatment-naïve CLL.

Results of the ELEVATE-TN trial showed that after a median follow-up of 28 months, the median progression-free survival (PFS) for the acalabrutinib (Calquence)-containing arms was not reached. In the chlorambucil plus obinutuzumab (Gazyva) arm, however, the median PFS was 22.6 months, says Bhat. The 2-year PFS rates were 93%, 87%, and 47% for acalabrutinib/obinutuzumab, single-agent acalabrutinib, and chemoimmunotherapy, respectively.

The comparison made between the 2 acalabrutinib-containing arms was not a preplanned analysis; however, in a post-hoc analysis, some separation between the curves was seen, Bhat adds. Additionally, the complete response (CR) rates were higher in the acalabrutinib/obinutuzumab arm at 13% compared with 1% patient in single agent acalabrutinib arm. Yet, results from the RESONATE-2 study indicated that CR rates with ibrutinib (Imbruvica), tend to increase over time. Long-term follow-up from the ELEVATE-TN are needed, but nonetheless, these are highly encouraging data, concludes Bhat.

Related Videos
Jerôme Fayette, MD, PhD, medical oncologist, Centre Léon Bérard
Jun Gong, MD, associate professor, medicine, medical oncologist, Gastrointestinal Disease Research Group, Pancreatic Cancer Research Group, Urologic Oncology Program, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai
Rebecca Klisovic, MD
Kedar Kirtane, MD, assistant member, Department of Head and Neck-Endocrine Oncology; medical director, Solid Tumor Cellular Therapy, Moffitt Cancer Center
Rohan Garje, MD
Cynthia Ma, MD, PhD
Combination of Zanubrutinib + Venetoclax for Treatment-naive CLL/SLL With del(17p) and/or TP53: Preliminary Results From SEQUOIA Arm D
Arya Mariam Roy, MBBS
Karl Semaan, MD, MSc
Bradley McGregor, MD, discusses findings from a phase 1b study of abemaciclib  in clear cell renal cell carcinoma.